Risk of Myeloma Still Small Despite Newly Revealed Gene Mutations
In the largest study to date, researchers from The Institute of Cancer Research in London identified eight new gene mutations increasing the risk of developing…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
EU OKs Extended Indication for Amgen’s Myeloma Drug Kyprolis
Global biotech firm Amgen has announced that the European Commission (EC) approved a variation to the marketing authorization for Kyprolis (carfilzomib) to be used in combination with…
Multiple Myeloma Treatment Outcomes May Improve with ‘Next-Generation Drug Candidates’, Review Says
Advances in the molecular understanding of multiple myeloma (MM) onset and disease development have enabled the production of effective drugs, such as bortezomib,thalidomide, and lenalidomide,…
One Multiple Myeloma Induction Therapy Stands Out in Test for Transplant-eligible Patients
Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible…
Relapsed/Refractory Multiple Myeloma Drug by Takeda Receives Negative Opinion from EMA
Takeda Pharmaceutical Company Limited has recently received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
Multiple Myeloma Among Topics in APSHO Educational Series for Healthcare Workers
The Advanced Practitioners Society for Hematology and Oncology (APSHO) is presenting a series of live continuing medical education (CME) meetings, titled the “APSHO Regional Lecture…
